| + |
Obatoclax mesylate | down-regulates activity 
chemical inhibition
|
BCL2L1 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-262023 |
|
|
in vitro |
|
| pmid |
sentence |
| 23515850 |
Obatoclax and its predecessor analogs bind to BCL-2, BCL-XL, BCL-w, BCL-B, BFL-1, and MCL-1 in vitro |
|
| Publications: |
1 |
Organism: |
In Vitro |
| + |
Obatoclax mesylate | down-regulates
chemical inhibition
|
BCL2 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-194952 |
|
|
Homo sapiens |
|
| pmid |
sentence |
| Other |
|
|
| Publications: |
1 |
Organism: |
Homo Sapiens |
| + |
Obatoclax mesylate | down-regulates activity
chemical inhibition
|
MCL1 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-262025 |
|
|
in vitro |
|
| pmid |
sentence |
| 23515850 |
Obatoclax and its predecessor analogs bind to BCL-2, BCL-XL, BCL-w, BCL-B, BFL-1, and MCL-1 in vitro|The ability of obatoclax to inhibit MCL-1 may be particularly important, given that several hematological malignancies appear to depend on this protein for survival, such as acute lymphoblastic leukemia (ALL),44 CLL,44 multiple myeloma,45 and diffuse large B-cell lymphoma (DLBCL) |
|
| Publications: |
1 |
Organism: |
In Vitro |
| + |
Obatoclax mesylate | down-regulates activity
chemical inhibition
|
BCL2 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-262022 |
|
|
in vitro |
|
| pmid |
sentence |
| 23515850 |
Obatoclax and its predecessor analogs bind to BCL-2, BCL-XL, BCL-w, BCL-B, BFL-1, and MCL-1 in vitro |
|
| Publications: |
1 |
Organism: |
In Vitro |
| + |
Obatoclax mesylate | down-regulates activity
chemical inhibition
|
BCL2L2 |
0.8 |
| Identifier |
Residue |
Sequence |
Organism |
Cell Line |
| SIGNOR-262024 |
|
|
in vitro |
|
| pmid |
sentence |
| 23515850 |
Obatoclax and its predecessor analogs bind to BCL-2, BCL-XL, BCL-w, BCL-B, BFL-1, and MCL-1 in vitro |
|
| Publications: |
1 |
Organism: |
In Vitro |
3.0
Obatoclax mesylate